Company / Cost of Revenue
BridgeBio Pharma, Inc. Cost of Revenue History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$21.0M
FY2025
5-year range
$2.7M / $21.0M
FY2021-FY2025
Trend
+440.5%
vs FY2024
Sector context
#63 of 85
Health Care
What the data says
Cost of Revenue changed +441% YoY in FY2025, a notable deviation from the 4-year average annual change of +120%.
Based on SEC 10-K filings.
$21M in FY2025 with a 3-year CAGR of +82.8%.
Increased from $3M to $21M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +82.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#23 of 85 in Health CareTop 26% of 85This company $21.0M Sector average $2.0B
▼
-98.9% below sector average
Key checks
Key Insights
- 3-year CAGR of +82.8%, indicating consistent growth.
- In FY2025, cost of revenue increased 440.5% year-over-year.
- Ranks #63 out of 85 companies in the Health Care sector.
- Lowest cost of revenue in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $21.0M | +440.5% |
| FY2024 | $3.9M | +24.5% |
| FY2023 | $3.1M | -9.3% |
| FY2022 | $3.4M | +25.6% |
| FY2021 | $2.7M | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026